Vanc Pharmaceuticals Inc. (SEC Filing Page | XBRL Cloud Viewer | XBRL Instance)

Line Label Object Class Period Type Balance Report ElementName
1 000010 - Document - Document and Entity Information Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_DocumentDocumentAndEntityInformation
2 Implied Table Table

*

*

 implied:Table
3 Details Abstract us-gaap:TextBlockAbstract
4 Registrant Name Concept (Text/String) For Period dei:EntityRegistrantName
5 Registrant CIK Concept (CIK Number) For Period dei:EntityCentralIndexKey
6 SEC Form Concept (Submission Type) For Period dei:DocumentType
7 Period End date Concept (Date) For Period dei:DocumentPeriodEndDate
8 Fiscal Year End Concept (Month/Day) For Period dei:CurrentFiscalYearEndDate
9 Trading Symbol Concept (Text/String) For Period dei:TradingSymbol
10 Tax Identification Number (TIN) Concept (Nine Digit Item) For Period dei:EntityTaxIdentificationNumber
11 Number of common stock shares outstanding Concept (Shares) As Of dei:EntityCommonStockSharesOutstanding
12 Public Float Concept (Monetary) As Of Credit dei:EntityPublicFloat
13 Filer Category Concept (Filer Category) For Period dei:EntityFilerCategory
14 Current with reporting Concept (Yes/No) For Period dei:EntityCurrentReportingStatus
15 Voluntary filer Concept (Yes/No) For Period dei:EntityVoluntaryFilers
16 Well-known Seasoned Issuer Concept (Yes/No) For Period dei:EntityWellKnownSeasonedIssuer
17 Amendment Description Concept (Text/String) For Period dei:AmendmentDescription
18 Amendment Flag Concept (Yes/No) For Period dei:AmendmentFlag
19 Document Fiscal Year Focus Concept (Year) For Period dei:DocumentFiscalYearFocus
20 Document Fiscal Period Focus Concept (Fiscal Period) For Period dei:DocumentFiscalPeriodFocus
21 Contained File Information, File Number Concept (Text/String) For Period dei:ContainedFileInformationFileNumber
22 Entity Home Country ISO Code Concept (Country) For Period dei:EntityHomeCountryISOCode
23 Entity Address, Address Line One Concept (Text/String) For Period dei:EntityAddressAddressLine1
24 Entity Address, City or Town Concept (Text/String) For Period dei:EntityAddressCityOrTown
25 Entity Address, State or Province Concept (Text/String) For Period dei:EntityAddressStateOrProvince
26 Entity Address, Postal Zip Code Concept (Text/String) For Period dei:EntityAddressPostalZipCode
27 Entity Address, Country Concept (Text/String) For Period dei:EntityAddressCountry
28 Contact Personnel Name Concept (Text/String) For Period dei:ContactPersonnelName
29 City Area Code Concept (Text/String) For Period dei:CityAreaCode
30 Local Phone Number Concept (Text/String) For Period dei:LocalPhoneNumber
31 Contact Personnel Email Address Concept (Text/String) For Period dei:ContactPersonnelEmailAddress
32 Entity Address, Address Description Concept (Text/String) For Period dei:EntityAddressAddressDescription
33 Entity Reporting Currency ISO Code Concept (Currency) For Period dei:EntityReportingCurrencyISOCode
34 000020 - Statement - Consolidated Statements of Financial Position Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_ConsolidatedStatementsOfFinancialPosition
35 Implied Table Table

*

*

 implied:Table
36 Details Abstract us-gaap:TextBlockAbstract
37 ASSETS Abstract ifrs-full:AssetsAbstract
38 Current Assets Abstract ifrs-full:CurrentAssetsAbstract
39 Cash and cash equivalents Concept (Monetary) As Of Debit ifrs-full:CashAndCashEquivalents
40 Accounts receivable Concept (Monetary) As Of Debit ifrs-full:TradeAndOtherCurrentReceivables
41 Prepaid expenses and deposits Concept (Monetary) As Of Debit ifrs-full:CurrentPrepaidExpenses
42 Inventories Concept (Monetary) As Of Debit ifrs-full:Inventories
43 Current assets Concept (Monetary) As Of Debit ifrs-full:CurrentAssets
44 Equipment Concept (Monetary) As Of Debit ifrs-full:PropertyPlantAndEquipment
45 Intangible assets Concept (Monetary) As Of Debit ifrs-full:IntangibleAssetsAndGoodwill
46 Total Assets Concept (Monetary) As Of Debit ifrs-full:Assets
47 LIABILITIES Abstract ifrs-full:LiabilitiesAbstract
48 Current Liabilities Abstract ifrs-full:CurrentLiabilitiesAbstract
49 Accounts payable and accrued liabilities Concept (Monetary) As Of Credit ifrs-full:TradeAndOtherCurrentPayables
50 Asset acquisition liability Concept (Monetary) As Of Credit ifrs-full:OtherLiabilities
51 Liabilities Concept (Monetary) As Of Credit ifrs-full:Liabilities
52 SHAREHOLDERS' EQUITY Abstract ifrs-full:EquityAbstract
53 Share capital Concept (Monetary) As Of Credit ifrs-full:IssuedCapital
54 Shares to be issued Concept (Monetary) As Of Credit ifrs-full:OtherReserves
55 Reserves Concept (Monetary) As Of Credit ifrs-full:CapitalReserve
56 Deficit Concept (Monetary) As Of Credit ifrs-full:RetainedEarnings
57 Equity Concept (Monetary) As Of Credit ifrs-full:Equity
58 Total Liabilities and Shareholders' Equity Concept (Monetary) As Of Credit ifrs-full:EquityAndLiabilities
59 000030 - Statement - Consolidated Statements of Operations and Comprehensive Loss Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_ConsolidatedStatementsOfOperationsAndComprehensiveLoss
60 Implied Table Table

*

*

 implied:Table
61 Details Abstract us-gaap:TextBlockAbstract
62 Revenue Abstract ifrs-full:RevenueAbstract
63 Sales Concept (Monetary) For Period Credit ifrs-full:RevenueFromSaleOfGoods
64 Marketing, promotional incentives Concept (Monetary) For Period Debit ifrs-full:SalesAndMarketingExpense
65 Net sales Concept (Monetary) For Period Credit ifrs-full:RevenueAndOperatingIncome
66 Cost of Sales Concept (Monetary) For Period Debit ifrs-full:CostOfSales
67 Gross Profit Concept (Monetary) For Period Credit ifrs-full:GrossProfit
68 Expenses Abstract ifrs-full:ExpenseByNatureAbstract
69 Product registration and development Concept (Monetary) For Period Debit ifrs-full:ResearchAndDevelopmentExpense
70 Selling and marketing Concept (Monetary) For Period Debit ifrs-full:SellingExpense
71 General and administrative Concept (Monetary) For Period Debit ifrs-full:GeneralAndAdministrativeExpense
72 Share-based compensation Concept (Monetary) For Period Debit ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
73 Expenses, by nature Concept (Monetary) For Period Debit ifrs-full:ExpenseByNature
74 Other income (expense) Abstract ifrs-full:FeeIncomeAndExpenseAbstract
75 Finance costs Concept (Monetary) For Period Debit ifrs-full:FinanceCosts
76 Interest income Concept (Monetary) For Period Credit ifrs-full:RevenueFromInterest
77 Other income Concept (Monetary) For Period Credit ifrs-full:OtherIncome
78 Write-down of inventories Concept (Monetary) For Period Debit ifrs-full:WritedownsReversalsOfInventories
79 Impairment of intellectual property Concept (Monetary) For Period ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
80 Net loss and comprehensive loss for the period Concept (Monetary) For Period Credit ifrs-full:ProfitLoss
81 Basic and Diluted Loss Per Share Concept (Share) For Period ifrs-full:BasicAndDilutedEarningsLossPerShare
82 Weighted Average Number of Common Shares Outstanding Concept (Shares) For Period ifrs-full:WeightedAverageShares
83 000040 - Statement - Consolidated Statements of Changes in Shareholders' Equity Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_ConsolidatedStatementsOfChangesInShareholdersEquity
84 Statement Table

*

*

 us-gaap:StatementTable
85 Components of equity Axis ifrs-full:ComponentsOfEquityAxis
86 Equity Member ifrs-full:EquityMember
87 Shares to be Issued Member ifrs-full:CapitalReserveMember
88 Warrant Reserve Member ifrs-full:ReserveOfEquityComponentOfConvertibleInstrumentsMember
89 Option Reserve Member ifrs-full:MiscellaneousOtherReservesMember
90 Deficit Member ifrs-full:RetainedEarningsMember
91 Issued capital Member ifrs-full:IssuedCapitalMember
92 Statement [Line Items] LineItems us-gaap:StatementLineItems
93 Equity at beginning of period Concept (Monetary) As Of Credit ifrs-full:Equity
94 Number of shares outstanding at beginning of period Concept (Shares) As Of ifrs-full:NumberOfSharesOutstanding
95 Issue of equity Concept (Monetary) For Period Credit ifrs-full:IssueOfEquity
96 Shares issued for Cash Concept (Shares) For Period fil:SharesIssuedForCash
97 For exercise of options Concept (Monetary) For Period Credit ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
98 Shares issued for Exercise of Options Concept (Shares) For Period fil:SharesIssuedForExerciseOfOptions
99 For exercise of warrants Concept (Monetary) For Period Credit ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
100 Shares issued for Exercise of Warrants Concept (Shares) For Period fil:SharesIssuedForExerciseOfWarrants
101 Share issuance costs Concept (Monetary) For Period Debit ifrs-full:ShareIssueRelatedCost
102 Change of warrants term Concept (Monetary) For Period Credit ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
103 Acquisition of HealthTab Inc. Concept (Monetary) For Period Credit ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary
104 Increase (decrease) through share-based payment transactions, equity Concept (Monetary) For Period Credit ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
105 Net loss and comprehensive loss for the period Concept (Monetary) For Period Credit ifrs-full:ProfitLoss
106 Number of shares outstanding at end of period Concept (Shares) As Of ifrs-full:NumberOfSharesOutstanding
107 Equity at end of period Concept (Monetary) As Of Credit ifrs-full:Equity
108 000050 - Statement - Consolidated Statements of Cash Flows Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_ConsolidatedStatementsOfCashFlows
109 Implied Table Table

*

*

 implied:Table
110 Details Abstract us-gaap:TextBlockAbstract
111 Operating Activities Abstract ifrs-full:CashFlowsFromUsedInOperatingActivitiesAbstract
112 Net loss and comprehensive loss for the period Concept (Monetary) For Period Credit ifrs-full:ProfitLoss
113 Adjustments to reconcile profit (loss) Abstract ifrs-full:AdjustmentsForReconcileProfitLossAbstract
114 Adjustments for amortisation expense Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForAmortisationExpense
115 Adjustments for share-based payments Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForSharebasedPayments
116 Write-downs (reversals of write-downs) of inventories Concept (Monetary) For Period Debit ifrs-full:WritedownsReversalsOfInventories
117 Impairment of intellectual property Concept (Monetary) For Period ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
118 Changes in Non-Cash Working Capital Items Abstract fil:ChangesInNonCashWorkingCapitalItemsAbstract
119 Adjustments for decrease (increase) in trade and other receivables Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
120 Adjustment for change in Prepaid expenses and deposits Concept (Monetary) For Period Credit fil:AdjustmentForChangeInPrepaidExpensesAndDeposits
121 Adjustments for decrease (increase) in inventories Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
122 Adjustment for change in Accounts payable and Accrued liabilities Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable
123 Net cash used in operating activities Concept (Monetary) For Period ifrs-full:CashFlowsFromUsedInOperatingActivities
124 Investing Activities Abstract ifrs-full:CashFlowsFromUsedInInvestingActivitiesAbstract
125 Purchase of equipment Concept (Monetary) For Period Credit ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
126 Acquisition, net of cash received Concept (Monetary) For Period Credit ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities
127 Net cash used in investing activities Concept (Monetary) For Period Debit ifrs-full:CashFlowsFromUsedInInvestingActivities
128 Financing Activities Abstract ifrs-full:CashFlowsFromUsedInFinancingActivitiesAbstract
129 Proceeds from issuance of shares, net Concept (Monetary) For Period Debit ifrs-full:ProceedsFromIssuingShares
130 Proceeds from exercise of options Concept (Monetary) For Period Debit ifrs-full:ProceedsFromExerciseOfOptions
131 Proceeds from exercise of warrants Concept (Monetary) For Period Credit fil:ProceedsFromExerciseOfWarrants
132 Repayment of promissory notes Concept (Monetary) For Period Credit ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
133 Net cash provided by financing activities Concept (Monetary) For Period Debit ifrs-full:CashFlowsFromUsedInFinancingActivities
134 Increase (Decrease) in Cash Concept (Monetary) For Period Debit ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
135 Cash and cash equivalents at beginning of period Concept (Monetary) As Of Debit ifrs-full:CashAndCashEquivalents
136 Cash and cash equivalents at end of period Concept (Monetary) As Of Debit ifrs-full:CashAndCashEquivalents
137 000060 - Statement - Components of Cash and Cash Equivalents Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_ComponentsOfCashAndCashEquivalents
138 Implied Table Table

*

*

 implied:Table
139 Details Abstract us-gaap:TextBlockAbstract
140 Cash and Cash Equivalents Consist of: Abstract ifrs-full:CashAndCashEquivalentsAbstract
141 Cash Concept (Monetary) As Of Debit ifrs-full:Cash
142 Guaranteed Investment Certificates Concept (Monetary) As Of Debit ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
143 Cash and cash equivalents Concept (Monetary) As Of Debit ifrs-full:CashAndCashEquivalents
144 000070 - Disclosure - 1. NATURE OF OPERATIONS AND GOING CONCERN Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure1NATUREOFOPERATIONSANDGOINGCONCERN
145 Implied Table Table

*

*

 implied:Table
146 Notes Abstract us-gaap:DisclosureTextBlockAbstract
147 1. NATURE OF OPERATIONS AND GOING CONCERN Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory
148 000080 - Disclosure - 2. BASIS OF PRESENTATION Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure2BASISOFPRESENTATION
149 Implied Table Table

*

*

 implied:Table
150 Notes Abstract us-gaap:DisclosureTextBlockAbstract
151 2. BASIS OF PRESENTATION Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfReclassificationsOrChangesInPresentationExplanatory
152 000090 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure3SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES
153 Implied Table Table

*

*

 implied:Table
154 Notes Abstract us-gaap:DisclosureTextBlockAbstract
155 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory
156 000100 - Disclosure - 4. ACQUISITION Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure4ACQUISITION
157 Implied Table Table

*

*

 implied:Table
158 Notes Abstract us-gaap:DisclosureTextBlockAbstract
159 4. ACQUISITION Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfBusinessCombinationsExplanatory
160 000110 - Disclosure - 5. ACCOUNTS RECEIVABLE Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure5ACCOUNTSRECEIVABLE
161 Implied Table Table

*

*

 implied:Table
162 Notes Abstract us-gaap:DisclosureTextBlockAbstract
163 5. ACCOUNTS RECEIVABLE Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory
164 000120 - Disclosure - 6. PREPAID EXPENSES AND DEPOSITS Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure6PREPAIDEXPENSESANDDEPOSITS
165 Implied Table Table

*

*

 implied:Table
166 Notes Abstract us-gaap:DisclosureTextBlockAbstract
167 6. PREPAID EXPENSES AND DEPOSITS Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory
168 000130 - Disclosure - 7. INVENTORIES Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure7INVENTORIES
169 Implied Table Table

*

*

 implied:Table
170 Notes Abstract us-gaap:DisclosureTextBlockAbstract
171 7. INVENTORIES Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfInventoriesExplanatory
172 000140 - Disclosure - 8. EQUIPMENT Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure8EQUIPMENT
173 Implied Table Table

*

*

 implied:Table
174 Notes Abstract us-gaap:DisclosureTextBlockAbstract
175 8. EQUIPMENT Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory
176 000150 - Disclosure - 9. INTANGIBLE ASSETS Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure9INTANGIBLEASSETS
177 Implied Table Table

*

*

 implied:Table
178 Notes Abstract us-gaap:DisclosureTextBlockAbstract
179 9. INTANGIBLE ASSETS Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfIntangibleAssetsExplanatory
180 000160 - Disclosure - 10. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure10ACCOUNTSPAYABLEANDACCRUEDLIABILITIES
181 Implied Table Table

*

*

 implied:Table
182 Notes Abstract us-gaap:DisclosureTextBlockAbstract
183 10. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory
184 000170 - Disclosure - 11. SHAREHOLDERS' EQUITY Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure11SHAREHOLDERSEQUITY
185 Implied Table Table

*

*

 implied:Table
186 Notes Abstract us-gaap:DisclosureTextBlockAbstract
187 11. SHAREHOLDERS' EQUITY Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfFairValueMeasurementOfEquityExplanatory
188 000180 - Disclosure - 12. PRODUCT REGISTRATION AND DEVELOPMENT Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure12PRODUCTREGISTRATIONANDDEVELOPMENT
189 Implied Table Table

*

*

 implied:Table
190 Notes Abstract us-gaap:DisclosureTextBlockAbstract
191 12. PRODUCT REGISTRATION AND DEVELOPMENT Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory
192 000190 - Disclosure - 13. SELLING AND MARKETING EXPENSES Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure13SELLINGANDMARKETINGEXPENSES
193 Implied Table Table

*

*

 implied:Table
194 Notes Abstract us-gaap:DisclosureTextBlockAbstract
195 13. SELLING AND MARKETING EXPENSES Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory
196 000200 - Disclosure - 14. GENERAL AND ADMINISTRATIVE EXPENSES Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure14GENERALANDADMINISTRATIVEEXPENSES
197 Implied Table Table

*

*

 implied:Table
198 Notes Abstract us-gaap:DisclosureTextBlockAbstract
199 14. GENERAL AND ADMINISTRATIVE EXPENSES Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory
200 000210 - Disclosure - 15. RELATED PARTY TRANSACTIONS Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure15RELATEDPARTYTRANSACTIONS
201 Implied Table Table

*

*

 implied:Table
202 Notes Abstract us-gaap:DisclosureTextBlockAbstract
203 15. RELATED PARTY TRANSACTIONS Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfRelatedPartyExplanatory
204 000220 - Disclosure - 16. CAPITAL DISCLOSURES Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure16CAPITALDISCLOSURES
205 Implied Table Table

*

*

 implied:Table
206 Notes Abstract us-gaap:DisclosureTextBlockAbstract
207 16. CAPITAL DISCLOSURES Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfIssuedCapitalExplanatory
208 000230 - Disclosure - 17. COMMITMENTS Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure17COMMITMENTS
209 Implied Table Table

*

*

 implied:Table
210 Notes Abstract us-gaap:DisclosureTextBlockAbstract
211 17. COMMITMENTS Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfCommitmentsExplanatory
212 000240 - Disclosure - 18. FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure18FINANCIALINSTRUMENTSANDFINANCIALRISKMANAGEMENT
213 Implied Table Table

*

*

 implied:Table
214 Notes Abstract us-gaap:DisclosureTextBlockAbstract
215 18. FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfFinancialInstrumentsExplanatory
216 000250 - Disclosure - 19. SUPPLEMENTAL CASH FLOW INFORMATION Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure19SUPPLEMENTALCASHFLOWINFORMATION
217 Implied Table Table

*

*

 implied:Table
218 Notes Abstract us-gaap:DisclosureTextBlockAbstract
219 19. SUPPLEMENTAL CASH FLOW INFORMATION Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfCashFlowStatementExplanatory
220 000260 - Disclosure - 20. INCOME TAXES Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure20INCOMETAXES
221 Implied Table Table

*

*

 implied:Table
222 Notes Abstract us-gaap:DisclosureTextBlockAbstract
223 20. INCOME TAXES Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfIncomeTaxExplanatory
224 000270 - Disclosure - 21. SUBSEQUENT EVENTS Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure21SUBSEQUENTEVENTS
225 Implied Table Table

*

*

 implied:Table
226 Notes Abstract us-gaap:DisclosureTextBlockAbstract
227 21. SUBSEQUENT EVENTS Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory
228 000280 - Disclosure - 2. BASIS OF PRESENTATION: Statement of Compliance and basis of presentation (Policies) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure2BASISOFPRESENTATIONStatementOfComplianceAndBasisOfPresentationPolicies
229 Implied Table Table

*

*

 implied:Table
230 Policies Abstract us-gaap:PolicyTextBlockAbstract
231 Statement of Compliance and basis of presentation Concept (Text Block (HTML)) For Period ifrs-full:StatementOfIFRSCompliance
232 000290 - Disclosure - 2. BASIS OF PRESENTATION: Basis of presentation (Policies) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure2BASISOFPRESENTATIONBasisOfPresentationPolicies
233 Implied Table Table

*

*

 implied:Table
234 Policies Abstract us-gaap:PolicyTextBlockAbstract
235 Basis of presentation Concept (Text Block (HTML)) For Period us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
236 000300 - Disclosure - 2. BASIS OF PRESENTATION: Basis of consolidation (Policies) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure2BASISOFPRESENTATIONBasisOfConsolidationPolicies
237 Implied Table Table

*

*

 implied:Table
238 Policies Abstract us-gaap:PolicyTextBlockAbstract
239 Basis of consolidation Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfBasisOfConsolidationExplanatory
240 000310 - Disclosure - 2. BASIS OF PRESENTATION: Accounting standards issued, but not yet in effective (Policies) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure2BASISOFPRESENTATIONAccountingStandardsIssuedButNotYetInEffectivePolicies
241 Implied Table Table

*

*

 implied:Table
242 Policies Abstract us-gaap:PolicyTextBlockAbstract
243 Accounting standards issued, but not yet in effective Concept (Text Block (HTML)) For Period fil:AccountingStandardsIssuedButNotYetInEffectiveTextBlock
244 000320 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Revenue recognition (Policies) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure3SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionPolicies
245 Implied Table Table

*

*

 implied:Table
246 Policies Abstract us-gaap:PolicyTextBlockAbstract
247 Revenue recognition Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue
248 000330 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Foreign currency (Policies) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure3SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESForeignCurrencyPolicies
249 Implied Table Table

*

*

 implied:Table
250 Policies Abstract us-gaap:PolicyTextBlockAbstract
251 Foreign currency Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory
252 000340 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Cash equivalents (Policies) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure3SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashEquivalentsPolicies
253 Implied Table Table

*

*

 implied:Table
254 Policies Abstract us-gaap:PolicyTextBlockAbstract
255 Cash equivalents Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents
256 000350 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Inventory (Policies) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure3SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESInventoryPolicies
257 Implied Table Table

*

*

 implied:Table
258 Policies Abstract us-gaap:PolicyTextBlockAbstract
259 Inventory Concept (Text Block (HTML)) For Period us-gaap:InventorySuppliesPolicy
260 000360 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Equipment (Policies) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure3SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEquipmentPolicies
261 Implied Table Table

*

*

 implied:Table
262 Policies Abstract us-gaap:PolicyTextBlockAbstract
263 Equipment Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory
264 000370 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Intangible assets (Policies) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure3SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsPolicies
265 Implied Table Table

*

*

 implied:Table
266 Policies Abstract us-gaap:PolicyTextBlockAbstract
267 Intangible assets Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory
268 000380 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Share-based payments (Policies) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure3SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESShareBasedPaymentsPolicies
269 Implied Table Table

*

*

 implied:Table
270 Policies Abstract us-gaap:PolicyTextBlockAbstract
271 Share-based payments Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory
272 000390 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Share capital (Policies) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure3SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESShareCapitalPolicies
273 Implied Table Table

*

*

 implied:Table
274 Policies Abstract us-gaap:PolicyTextBlockAbstract
275 Share capital Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory
276 000400 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Loss per share (Policies) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure3SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLossPerSharePolicies
277 Implied Table Table

*

*

 implied:Table
278 Policies Abstract us-gaap:PolicyTextBlockAbstract
279 Loss per share Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory
280 000410 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Income taxes (Policies) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure3SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesPolicies
281 Implied Table Table

*

*

 implied:Table
282 Policies Abstract us-gaap:PolicyTextBlockAbstract
283 Income taxes Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory
284 000420 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Financial Instruments (Policies) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure3SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsPolicies
285 Implied Table Table

*

*

 implied:Table
286 Policies Abstract us-gaap:PolicyTextBlockAbstract
287 Financial Instruments Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory
288 000430 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Impairment of equipment and intangible assets (Policies) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure3SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESImpairmentOfEquipmentAndIntangibleAssetsPolicies
289 Implied Table Table

*

*

 implied:Table
290 Policies Abstract us-gaap:PolicyTextBlockAbstract
291 Impairment of equipment and intangible assets Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory
292 000440 - Disclosure - 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Significant accounting estimates and judgments (Policies) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure3SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSignificantAccountingEstimatesAndJudgmentsPolicies
293 Implied Table Table

*

*

 implied:Table
294 Policies Abstract us-gaap:PolicyTextBlockAbstract
295 Significant accounting estimates and judgments Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory
296 000450 - Disclosure - 1. NATURE OF OPERATIONS AND GOING CONCERN: Schedule of Loss, Deficit and Working Capital (Tables) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure1NATUREOFOPERATIONSANDGOINGCONCERNScheduleOfLossDeficitAndWorkingCapitalTables
297 Implied Table Table

*

*

 implied:Table
298 Tables/Schedules Abstract us-gaap:TableTextBlockSupplementAbstract
299 Schedule of Loss, Deficit and Working Capital Concept (Text Block (HTML)) For Period fil:ScheduleOfLossDeficitAndWorkingCapitalTextBlock
300 000460 - Disclosure - 4. ACQUISITION: Aggregate fair values of assets acquired and liabilities assumed in acquisition (Tables) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure4ACQUISITIONAggregateFairValuesOfAssetsAcquiredAndLiabilitiesAssumedInAcquisitionTables
301 Implied Table Table

*

*

 implied:Table
302 Tables/Schedules Abstract us-gaap:TableTextBlockSupplementAbstract
303 Aggregate fair values of assets acquired and liabilities assumed in acquisition Concept (Text Block (HTML)) For Period fil:AggregateFairValuesOfAssetsAcquiredAndLiabilitiesAssumedInAcquisitionTextBlock
304 000470 - Disclosure - 5. ACCOUNTS RECEIVABLE: Schedule of Accounts Receivable (Tables) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure5ACCOUNTSRECEIVABLEScheduleOfAccountsReceivableTables
305 Implied Table Table

*

*

 implied:Table
306 Tables/Schedules Abstract us-gaap:TableTextBlockSupplementAbstract
307 Schedule of Accounts Receivable Concept (Text Block (HTML)) For Period fil:ScheduleOfAccountsReceivableTextBlock
308 000480 - Disclosure - 7. INVENTORIES: Schedule of Inventory (Tables) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure7INVENTORIESScheduleOfInventoryTables
309 Implied Table Table

*

*

 implied:Table
310 Tables/Schedules Abstract us-gaap:TableTextBlockSupplementAbstract
311 Schedule of Inventory Concept (Text Block (HTML)) For Period fil:ScheduleOfInventoryTextBlock
312 000490 - Disclosure - 8. EQUIPMENT: Schedule of Equipment (Tables) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure8EQUIPMENTScheduleOfEquipmentTables
313 Implied Table Table

*

*

 implied:Table
314 Tables/Schedules Abstract us-gaap:TableTextBlockSupplementAbstract
315 Schedule of Equipment Concept (Text Block (HTML)) For Period fil:ScheduleOfEquipmentTextBlock
316 000500 - Disclosure - 9. INTANGIBLE ASSETS: Schedule of Intangible Assets (Tables) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure9INTANGIBLEASSETSScheduleOfIntangibleAssetsTables
317 Implied Table Table

*

*

 implied:Table
318 Tables/Schedules Abstract us-gaap:TableTextBlockSupplementAbstract
319 Schedule of Intangible Assets Concept (Text Block (HTML)) For Period fil:ScheduleOfIntangibleAssetsTextBlock
320 000510 - Disclosure - 10. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES: Schedule of accounts payable and accrued costs (Tables) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure10ACCOUNTSPAYABLEANDACCRUEDLIABILITIESScheduleOfAccountsPayableAndAccruedCostsTables
321 Implied Table Table

*

*

 implied:Table
322 Tables/Schedules Abstract us-gaap:TableTextBlockSupplementAbstract
323 Schedule of accounts payable and accrued costs Concept (Text Block (HTML)) For Period fil:ScheduleOfAccountsPayableAndAccruedCostsTextBlock
324 000520 - Disclosure - 11. SHAREHOLDERS' EQUITY: Schedule of changes in share options (Tables) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure11SHAREHOLDERSEQUITYScheduleOfChangesInShareOptionsTables
325 Implied Table Table

*

*

 implied:Table
326 Tables/Schedules Abstract us-gaap:TableTextBlockSupplementAbstract
327 Schedule of changes in share options Concept (Text Block (HTML)) For Period fil:ScheduleOfChangesInShareOptionsTextBlock
328 000530 - Disclosure - 11. SHAREHOLDERS' EQUITY: Schedule of share options outstanding and exercisable (Tables) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure11SHAREHOLDERSEQUITYScheduleOfShareOptionsOutstandingAndExercisableTables
329 Implied Table Table

*

*

 implied:Table
330 Tables/Schedules Abstract us-gaap:TableTextBlockSupplementAbstract
331 Schedule of share options outstanding and exercisable Concept (Text Block (HTML)) For Period fil:ScheduleOfShareOptionsOutstandingAndExercisableTextBlock
332 000540 - Disclosure - 11. SHAREHOLDERS' EQUITY: Schedule of Share-based payments for options granted (Tables) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure11SHAREHOLDERSEQUITYScheduleOfShareBasedPaymentsForOptionsGrantedTables
333 Implied Table Table

*

*

 implied:Table
334 Tables/Schedules Abstract us-gaap:TableTextBlockSupplementAbstract
335 Schedule of Share-based payments for options granted Concept (Text Block (HTML)) For Period fil:ScheduleOfShareBasedPaymentsForOptionsGrantedTextBlock
336 000550 - Disclosure - 11. SHAREHOLDERS' EQUITY: Schedule of changes in warrants (Tables) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure11SHAREHOLDERSEQUITYScheduleOfChangesInWarrantsTables
337 Implied Table Table

*

*

 implied:Table
338 Tables/Schedules Abstract us-gaap:TableTextBlockSupplementAbstract
339 Schedule of changes in warrants Concept (Text Block (HTML)) For Period fil:ScheduleOfChangesInWarrantsTextBlock
340 000560 - Disclosure - 11. SHAREHOLDERS' EQUITY: Schedule of warrants outstanding and exercisable (Tables) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure11SHAREHOLDERSEQUITYScheduleOfWarrantsOutstandingAndExercisableTables
341 Implied Table Table

*

*

 implied:Table
342 Tables/Schedules Abstract us-gaap:TableTextBlockSupplementAbstract
343 Schedule of warrants outstanding and exercisable Concept (Text Block (HTML)) For Period fil:ScheduleOfwarrantsOutstandingAndExercisableTextBlock
344 000570 - Disclosure - 11. SHAREHOLDERS' EQUITY: Schedule of Fair Value of Finder's Warrants (Tables) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure11SHAREHOLDERSEQUITYScheduleOfFairValueOfFinderSWarrantsTables
345 Implied Table Table

*

*

 implied:Table
346 Tables/Schedules Abstract us-gaap:TableTextBlockSupplementAbstract
347 Schedule of Fair Value of Finder's Warrants Concept (Text Block (HTML)) For Period fil:ScheduleOfFairValueOfFinderSWarrantsTextBlock
348 000580 - Disclosure - 11. SHAREHOLDERS' EQUITY: Schedule of Assumptions in Fair Value Measurement of Warrants (Tables) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure11SHAREHOLDERSEQUITYScheduleOfAssumptionsInFairValueMeasurementOfWarrantsTables
349 Implied Table Table

*

*

 implied:Table
350 Tables/Schedules Abstract us-gaap:TableTextBlockSupplementAbstract
351 Schedule of Assumptions in Fair Value Measurement of Warrants Concept (Text Block (HTML)) For Period fil:ScheduleOfAssumptionsInFairValueMeasurementOfWarrantsTextBlock
352 000590 - Disclosure - 12. PRODUCT REGISTRATION AND DEVELOPMENT: Schedule of Product Registration and Development (Tables) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure12PRODUCTREGISTRATIONANDDEVELOPMENTScheduleOfProductRegistrationAndDevelopmentTables
353 Implied Table Table

*

*

 implied:Table
354 Tables/Schedules Abstract us-gaap:TableTextBlockSupplementAbstract
355 Schedule of Product Registration and Development Concept (Text Block (HTML)) For Period fil:ScheduleOfProductRegistrationAndDevelopmentTextBlock
356 000600 - Disclosure - 13. SELLING AND MARKETING EXPENSES: Schedule of Selling and Marketing Expense (Tables) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure13SELLINGANDMARKETINGEXPENSESScheduleOfSellingAndMarketingExpenseTables
357 Implied Table Table

*

*

 implied:Table
358 Tables/Schedules Abstract us-gaap:TableTextBlockSupplementAbstract
359 Schedule of Selling and Marketing Expense Concept (Text Block (HTML)) For Period fil:ScheduleOfSellingAndMarketingExpenseTextBlock
360 000610 - Disclosure - 14. GENERAL AND ADMINISTRATIVE EXPENSES: Schedule of General and Administrative Expenses (Tables) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure14GENERALANDADMINISTRATIVEEXPENSESScheduleOfGeneralAndAdministrativeExpensesTables
361 Implied Table Table

*

*

 implied:Table
362 Tables/Schedules Abstract us-gaap:TableTextBlockSupplementAbstract
363 Schedule of General and Administrative Expenses Concept (Text Block (HTML)) For Period fil:ScheduleOfGeneralAndAdministrativeExpensesTextBlock
364 000620 - Disclosure - 15. RELATED PARTY TRANSACTIONS: Schedule of Related Party Transactions (Tables) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure15RELATEDPARTYTRANSACTIONSScheduleOfRelatedPartyTransactionsTables
365 Implied Table Table

*

*

 implied:Table
366 Tables/Schedules Abstract us-gaap:TableTextBlockSupplementAbstract
367 Schedule of Related Party Transactions Concept (Text Block (HTML)) For Period fil:ScheduleOfRelatedPartyTransactionsTextBlock
368 000630 - Disclosure - 17. COMMITMENTS: Schedule of future minimum lease payments (Tables) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure17COMMITMENTSScheduleOfFutureMinimumLeasePaymentsTables
369 Implied Table Table

*

*

 implied:Table
370 Tables/Schedules Abstract us-gaap:TableTextBlockSupplementAbstract
371 Schedule of future minimum lease payments Concept (Text Block (HTML)) For Period fil:ScheduleOfFutureMinimumLeasePaymentsTextBlock
372 000640 - Disclosure - 18. FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT: Schedule of aging of accounts receivable (Tables) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure18FINANCIALINSTRUMENTSANDFINANCIALRISKMANAGEMENTScheduleOfAgingOfAccountsReceivableTables
373 Implied Table Table

*

*

 implied:Table
374 Tables/Schedules Abstract us-gaap:TableTextBlockSupplementAbstract
375 Schedule of aging of accounts receivable Concept (Text Block (HTML)) For Period fil:ScheduleOfAgingOfAccountsReceivableTextBlock
376 000650 - Disclosure - 19. SUPPLEMENTAL CASH FLOW INFORMATION: Schedule of Supplemental Cash Flow Information (Tables) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure19SUPPLEMENTALCASHFLOWINFORMATIONScheduleOfSupplementalCashFlowInformationTables
377 Implied Table Table

*

*

 implied:Table
378 Tables/Schedules Abstract us-gaap:TableTextBlockSupplementAbstract
379 Schedule of Supplemental Cash Flow Information Concept (Text Block (HTML)) For Period fil:ScheduleOfSupplementalCashFlowInformationTextBlock
380 000660 - Disclosure - 20. INCOME TAXES: Schedule of Income Tax Reconciliation (Tables) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure20INCOMETAXESScheduleOfIncomeTaxReconciliationTables
381 Implied Table Table

*

*

 implied:Table
382 Tables/Schedules Abstract us-gaap:TableTextBlockSupplementAbstract
383 Schedule of Income Tax Reconciliation Concept (Text Block (HTML)) For Period fil:ScheduleOfIncomeTaxReconciliationTextBlock
384 000670 - Disclosure - 20. INCOME TAXES: Schedule of Deferred Tax Assets and Liabilities (Tables) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure20INCOMETAXESScheduleOfDeferredTaxAssetsAndLiabilitiesTables
385 Implied Table Table

*

*

 implied:Table
386 Tables/Schedules Abstract us-gaap:TableTextBlockSupplementAbstract
387 Schedule of Deferred Tax Assets and Liabilities Concept (Text Block (HTML)) For Period fil:ScheduleOfDeferredTaxAssetsAndLiabilitiesTextBlock
388 000680 - Disclosure - 1. NATURE OF OPERATIONS AND GOING CONCERN (Details) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure1NATUREOFOPERATIONSANDGOINGCONCERNDetails
389 Statement Table

*

*

 us-gaap:StatementTable
390 Entity Listings, Exchange [Axis] Axis dei:EntityListingsExchangeAxis
391 Exchange Member dei:ExchangeDomain
392 TSX Venture Exchange Member fil:TsxVentureExchangeMember
393 OTCIQ Market Member fil:OtciqMarketMember
394 Statement [Line Items] LineItems us-gaap:StatementLineItems
395 Name of reporting entity or other means of identification Concept (Text/String) For Period ifrs-full:NameOfReportingEntityOrOtherMeansOfIdentification
396 Legal form of entity Concept (Text/String) For Period ifrs-full:LegalFormOfEntity
397 Domicile of entity Concept (Text/String) For Period ifrs-full:DomicileOfEntity
398 Entity Incorporation, Date of Incorporation Concept (Date) For Period dei:EntityIncorporationDateOfIncorporation
399 Trading Symbol Concept (Text/String) For Period dei:TradingSymbol
400 Entity Address, Address Line One Concept (Text/String) For Period dei:EntityAddressAddressLine1
401 Entity Address, City or Town Concept (Text/String) For Period dei:EntityAddressCityOrTown
402 Entity Address, State or Province Concept (Text/String) For Period dei:EntityAddressStateOrProvince
403 Entity Address, Postal Zip Code Concept (Text/String) For Period dei:EntityAddressPostalZipCode
404 Description of nature of entity's operations and principal activities Concept (Text/String) For Period ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities
405 Net loss and comprehensive loss for the period Concept (Monetary) For Period Credit ifrs-full:ProfitLoss
406 000690 - Disclosure - 1. NATURE OF OPERATIONS AND GOING CONCERN: Schedule of Loss, Deficit and Working Capital (Details) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure1NATUREOFOPERATIONSANDGOINGCONCERNScheduleOfLossDeficitAndWorkingCapitalDetails
407 Implied Table Table

*

*

 implied:Table
408 Details Abstract us-gaap:TextBlockAbstract
409 Net loss and comprehensive loss for the period Concept (Monetary) For Period Credit ifrs-full:ProfitLoss
410 Deficit Concept (Monetary) As Of Credit ifrs-full:RetainedEarnings
411 Working capital Concept (Monetary) As Of Debit fil:WorkingCapital
412 000700 - Disclosure - 4. ACQUISITION: Aggregate fair values of assets acquired and liabilities assumed in acquisition (Details) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure4ACQUISITIONAggregateFairValuesOfAssetsAcquiredAndLiabilitiesAssumedInAcquisitionDetails
413 Implied Table Table

*

*

 implied:Table
414 Details Abstract us-gaap:TextBlockAbstract
415 Purchase consideration Abstract fil:PurchaseConsiderationAbstract
416 Purchase consideration - Cash Concept (Monetary) As Of Debit fil:PurchaseConsiderationCash
417 Purchase consideration - Asset acquisition liability Concept (Monetary) As Of Debit fil:PurchaseConsiderationAssetAcquisitionLiability
418 Purchase consideration - Shares to be issued Concept (Monetary) As Of Debit fil:PurchaseConsiderationSharesToBeIssued
419 Purchase consideration - Acquisition costs Concept (Monetary) As Of Debit fil:PurchaseConsiderationAcquisitionCosts
420 Purchase consideration Concept (Monetary) As Of Debit fil:PurchaseConsideration
421 Net assets acquired Abstract fil:NetAssetsAcquiredAbstract
422 Net Assets Acquired - Cash Concept (Monetary) As Of Debit fil:NetAssetsAcquiredCash
423 Net Assets Acquired - Equipment Concept (Monetary) As Of Debit fil:NetAssetsAcquiredEquipment
424 Net Assets Acquired - Intangible assets Concept (Monetary) As Of Debit fil:NetAssetsAcquiredIntangibleAssets
425 Net Assets Acquired - Accounts payable and accrued liabilities Concept (Monetary) As Of Debit fil:NetAssetsAcquiredAccountsPayableAndAccruedLiabilities
426 Total net assets acquired Concept (Monetary) As Of Debit fil:NetAssetsAcquired
427 000710 - Disclosure - 5. ACCOUNTS RECEIVABLE: Schedule of Accounts Receivable (Details) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure5ACCOUNTSRECEIVABLEScheduleOfAccountsReceivableDetails
428 Implied Table Table

*

*

 implied:Table
429 Details Abstract us-gaap:TextBlockAbstract
430 Trade receivables Concept (Monetary) As Of Debit ifrs-full:TradeReceivables
431 GST receivable Concept (Monetary) As Of Debit fil:GstReceivable
432 Employee advances Concept (Monetary) As Of Debit fil:EmployeeAdvances
433 Accounts receivable Concept (Monetary) As Of Debit ifrs-full:TradeAndOtherCurrentReceivables
434 000720 - Disclosure - 6. PREPAID EXPENSES AND DEPOSITS (Details) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure6PREPAIDEXPENSESANDDEPOSITSDetails
435 Implied Table Table

*

*

 implied:Table
436 Details Abstract us-gaap:TextBlockAbstract
437 Deposits for inventory purchases and prepaid expense to vendors Concept (Monetary) As Of Debit fil:DepositsForInventoryPurchasesAndPrepaidExpenseToVendors
438 Prepaid Office Rent Concept (Monetary) As Of Debit fil:PrepaidOfficeRent
439 Prepaid business insurance Concept (Monetary) As Of Debit fil:PrepaidBusinessInsurance
440 000730 - Disclosure - 7. INVENTORIES: Schedule of Inventory (Details) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure7INVENTORIESScheduleOfInventoryDetails
441 Implied Table Table

*

*

 implied:Table
442 Details Abstract us-gaap:TextBlockAbstract
443 Work in process Concept (Monetary) As Of Debit fil:WorkInProcess
444 Finished goods Concept (Monetary) As Of Debit ifrs-full:FinishedGoods
445 Inventories Concept (Monetary) As Of Debit ifrs-full:Inventories
446 000740 - Disclosure - 8. EQUIPMENT: Schedule of Equipment (Details) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure8EQUIPMENTScheduleOfEquipmentDetails
447 Statement Table

*

*

 us-gaap:StatementTable
448 Classes of property, plant and equipment Axis ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis
449 Property, plant and equipment Member ifrs-full:PropertyPlantAndEquipmentMember
450 Office equipment Member ifrs-full:OfficeEquipmentMember
451 Computer equipment Member ifrs-full:ComputerEquipmentMember
452 Laboratory Equipment Member ifrs-full:OtherPropertyPlantAndEquipmentMember
453 Leasehold Improvements Member ifrs-full:PropertyPlantAndEquipmentUnderOperatingLeasesMember
454 Statement [Line Items] LineItems us-gaap:StatementLineItems
455 Equipment, Gross, start of period Concept (Monetary) As Of Debit fil:EquipmentGross
456 Additions other than through business combinations, property, plant and equipment Concept (Monetary) For Period Debit ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
457 Acquisitions through business combinations, property, plant and equipment Concept (Monetary) For Period Debit ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
458 Equipment, Gross, end of period Concept (Monetary) As Of Debit fil:EquipmentGross
459 Accumulated Amortization, start of period Concept (Monetary) As Of Debit fil:AccumulatedAmortization
460 Amortisation expense Concept (Monetary) For Period Debit ifrs-full:AmortisationExpense
461 Accumulated Amortization, end of period Concept (Monetary) As Of Debit fil:AccumulatedAmortization
462 Equipment, Carrying Value, start of period Concept (Monetary) As Of Debit ifrs-full:PropertyPlantAndEquipment
463 Equipment, Carrying Value, end of period Concept (Monetary) As Of Debit ifrs-full:PropertyPlantAndEquipment
464 000750 - Disclosure - 9. INTANGIBLE ASSETS: Schedule of Intangible Assets (Details) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure9INTANGIBLEASSETSScheduleOfIntangibleAssetsDetails
465 Implied Table Table

*

*

 implied:Table
466 Details Abstract us-gaap:TextBlockAbstract
467 Intangible Assets, Gross, start of period Concept (Monetary) As Of Debit fil:NetAssetsAcquiredIntangibleAssets
468 Acquired assets Concept (Monetary) For Period Debit ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill
469 Intangible Assets, Gross, end of period Concept (Monetary) As Of Debit fil:NetAssetsAcquiredIntangibleAssets
470 Intangible Assets, Accumulated Amortization, starting balance Concept (Monetary) As Of Debit fil:IntangibleAssetsAccumulatedAmortization
471 Intangible Assets, Amortization over period Concept (Monetary) For Period Credit fil:IntangibleAssetsAmortizationOverPeriod
472 Intangible Assets, Accumulated Amortization, ending balance Concept (Monetary) As Of Debit fil:IntangibleAssetsAccumulatedAmortization
473 Intangible Assets, Carrying Value, start of period Concept (Monetary) As Of Debit ifrs-full:IntangibleAssetsAndGoodwill
474 Intangible Assets, Carrying Value, end of period Concept (Monetary) As Of Debit ifrs-full:IntangibleAssetsAndGoodwill
475 000760 - Disclosure - 10. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES: Schedule of accounts payable and accrued costs (Details) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure10ACCOUNTSPAYABLEANDACCRUEDLIABILITIESScheduleOfAccountsPayableAndAccruedCostsDetails
476 Implied Table Table

*

*

 implied:Table
477 Details Abstract us-gaap:TextBlockAbstract
478 Trade accounts payable Concept (Monetary) As Of Credit fil:TradeAccountsPayable
479 Accrued liabilities Concept (Monetary) As Of Credit ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities
480 Accounts payable and accrued liabilities Concept (Monetary) As Of Credit ifrs-full:TradeAndOtherCurrentPayables
481 000770 - Disclosure - 11. SHAREHOLDERS' EQUITY (Details) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure11SHAREHOLDERSEQUITYDetails
482 Statement Table

*

*

 us-gaap:StatementTable
483 Classes of share capital Axis ifrs-full:ClassesOfShareCapitalAxis
484 Share capital Member ifrs-full:ClassesOfShareCapitalMember
485 Issue 1 Member fil:Issue1Member
486 Issue 2 Member fil:Issue2Member
487 Issue 3 Member fil:Issue3Member
488 Issue 4 Member fil:Issue4Member
489 Issue 5 Member fil:Issue5Member
490 Issue 6 Member fil:Issue6Member
491 Issue 7 Member fil:Issue7Member
492 Issue 8 Member fil:Issue8Member
493 Issue 9 Member fil:Issue9Member
494 Relating to options and warrants exercised Member fil:RelatingToOptionsAndWarrantsExercisedMember
495 Share-based payments for options granted Member fil:ShareBasedPaymentsForOptionsGrantedMember
496 Fair value of each warrant Member fil:FairValueOfEachWarrantMember
497 Range Axis ifrs-full:RangeAxis
498 Ranges Member ifrs-full:RangesMember
499 Bottom of range Member ifrs-full:BottomOfRangeMember
500 Top of range Member ifrs-full:TopOfRangeMember
501 Statement [Line Items] LineItems us-gaap:StatementLineItems
502 Date of Transaction Concept (Date) For Period fil:DateOfTransaction
503 Description of significant events and transactions Concept (Text/String) For Period ifrs-full:DescriptionOfSignificantEventsAndTransactions
504 Number of shares issued Concept (Shares) As Of ifrs-full:NumberOfSharesIssued
505 Par value per share Concept (Share) As Of ifrs-full:ParValuePerShare
506 Proceeds from issuance of shares, net Concept (Monetary) For Period Debit ifrs-full:ProceedsFromIssuingShares
507 Finder's fees Concept (Monetary) For Period Debit fil:FinderSFees
508 Warrants issued Concept (Shares) For Period fil:WarrantsIssued
509 Warrants issued, fair value Concept (Monetary) For Period Debit fil:WarrantsIssuedFairValue
510 Share issuance costs Concept (Monetary) For Period Debit ifrs-full:ShareIssueRelatedCost
511 Key management personnel compensation, share-based payment Concept (Monetary) For Period Debit ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
512 Fair Value Measurements, Valuation Techniques Concept (Text/String) For Period us-gaap:FairValueMeasurementsValuationTechniques
513 000780 - Disclosure - 11. SHAREHOLDERS' EQUITY: Schedule of changes in share options (Details) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure11SHAREHOLDERSEQUITYScheduleOfChangesInShareOptionsDetails
514 Statement Table

*

*

 us-gaap:StatementTable
515 Classes of financial instruments Axis ifrs-full:ClassesOfFinancialInstrumentsAxis
516 Financial instruments, class Member ifrs-full:ClassesOfFinancialInstrumentsMember
517 Share options including those granted to directors, officers, employees and consultants Member fil:ShareOptionsIncludingThoseGrantedToDirectorsOfficersEmployeesAndConsultantsMember
518 Statement [Line Items] LineItems us-gaap:StatementLineItems
519 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance Concept (Shares) As Of us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
520 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance Concept (Share) As Of us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
521 Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Concept (Shares) For Period us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
522 Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Concept (Share) For Period us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
523 Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Concept (Shares) For Period us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
524 Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Concept (Share) For Period us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
525 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Concept (Shares) For Period us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
526 Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Concept (Share) For Period us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
527 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance Concept (Shares) As Of us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
528 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance Concept (Share) As Of us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
529 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Concept (Shares) As Of us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
530 Weighted Average Exercise price at end of period Concept (Share) As Of fil:WeightedAverageExercisePriceAtEndOfPeriod
531 000790 - Disclosure - 11. SHAREHOLDERS' EQUITY: Schedule of share options outstanding and exercisable (Details) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure11SHAREHOLDERSEQUITYScheduleOfShareOptionsOutstandingAndExercisableDetails
532 Statement Table

*

*

 us-gaap:StatementTable
533 Classes of financial instruments Axis ifrs-full:ClassesOfFinancialInstrumentsAxis
534 Financial instruments, class Member ifrs-full:ClassesOfFinancialInstrumentsMember
535 Share Option 1 Member fil:ShareOption1Member
536 Share Option 2 Member fil:ShareOption2Member
537 Share Option 3 Member fil:ShareOption3Member
538 Share Option 4 Member fil:ShareOption4Member
539 Share Option 5 Member fil:ShareOption5Member
540 Share Option 6 Member fil:ShareOption6Member
541 Share Option 7 Member fil:ShareOption7Member
542 Statement [Line Items] LineItems us-gaap:StatementLineItems
543 Share Options, Exercise Price Concept (Share) As Of fil:ShareOptionsExercisePrice
544 Share Options, Expiry Date Concept (Date) For Period fil:ShareOptionsExpiryDate
545 Share Options, Outstanding Concept (Shares) For Period fil:ShareOptionsOutstanding
546 Share Options, Exercisable Concept (Shares) For Period fil:ShareOptionsExercisable
547 000800 - Disclosure - 11. SHAREHOLDERS' EQUITY: Schedule of Share-based payments for options granted (Details) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure11SHAREHOLDERSEQUITYScheduleOfShareBasedPaymentsForOptionsGrantedDetails
548 Statement Table

*

*

 us-gaap:StatementTable
549 Classes of share capital Axis ifrs-full:ClassesOfShareCapitalAxis
550 Share capital Member ifrs-full:ClassesOfShareCapitalMember
551 Share-based payments for options granted Member fil:ShareBasedPaymentsForOptionsGrantedMember
552 Range Axis ifrs-full:RangeAxis
553 Ranges Member ifrs-full:RangesMember
554 Bottom of range Member ifrs-full:BottomOfRangeMember
555 Top of range Member ifrs-full:TopOfRangeMember
556 Statement [Line Items] LineItems us-gaap:StatementLineItems
557 Expected life Concept (xbrli:durationItemType) For Period us-gaap:FairValueAssumptionsExpectedTerm
558 Volatility Concept (Percent) For Period us-gaap:FairValueAssumptionsExpectedVolatilityRate
559 Dividend yield Concept (Percent) For Period us-gaap:FairValueAssumptionsExpectedDividendRate
560 Risk-free interest rate Concept (Percent) For Period us-gaap:FairValueAssumptionsRiskFreeInterestRate
561 000810 - Disclosure - 11. SHAREHOLDERS' EQUITY: Schedule of changes in warrants (Details) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure11SHAREHOLDERSEQUITYScheduleOfChangesInWarrantsDetails
562 Statement Table

*

*

 us-gaap:StatementTable
563 Classes of financial instruments Axis ifrs-full:ClassesOfFinancialInstrumentsAxis
564 Financial instruments, class Member ifrs-full:ClassesOfFinancialInstrumentsMember
565 Warrants entitling the holders to acquire common shares Member fil:WarrantsEntitlingTheHoldersToAcquireCommonSharesMember
566 Statement [Line Items] LineItems us-gaap:StatementLineItems
567 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance Concept (Shares) As Of us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
568 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance Concept (Share) As Of us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
569 Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Concept (Shares) For Period us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
570 Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Concept (Share) For Period us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
571 Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Concept (Shares) For Period us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
572 Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Concept (Share) For Period us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
573 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Concept (Shares) For Period us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
574 Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Concept (Share) For Period us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
575 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance Concept (Shares) As Of us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
576 Weighted Average Exercise price at end of period Concept (Share) As Of fil:WeightedAverageExercisePriceAtEndOfPeriod
577 000820 - Disclosure - 11. SHAREHOLDERS' EQUITY: Schedule of warrants outstanding and exercisable (Details) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure11SHAREHOLDERSEQUITYScheduleOfWarrantsOutstandingAndExercisableDetails
578 Statement Table

*

*

 us-gaap:StatementTable
579 Classes of financial instruments Axis ifrs-full:ClassesOfFinancialInstrumentsAxis
580 Financial instruments, class Member ifrs-full:ClassesOfFinancialInstrumentsMember
581 Warrant 1 Member fil:Warrant1Member
582 Warrant 2 Member fil:Warrant2Member
583 Warrant 3 Member fil:Warrant3Member
584 Statement [Line Items] LineItems us-gaap:StatementLineItems
585 Warrant Exercise Price Concept (Share) For Period fil:WarrantExercisePrice
586 Warrant Expiry Date Concept (Date) For Period fil:WarrantExpiryDate
587 Warrants outstanding Concept (Shares) As Of fil:WarrantsOutstanding
588 000830 - Disclosure - 11. SHAREHOLDERS' EQUITY: Schedule of Fair Value of Finder's Warrants (Details) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure11SHAREHOLDERSEQUITYScheduleOfFairValueOfFinderSWarrantsDetails
589 Statement Table

*

*

 us-gaap:StatementTable
590 Classes of share capital Axis ifrs-full:ClassesOfShareCapitalAxis
591 Share capital Member ifrs-full:ClassesOfShareCapitalMember
592 Fair value of finder's warrants Member fil:FairValueOfFinderSWarrantsMember
593 Range Axis ifrs-full:RangeAxis
594 Ranges Member ifrs-full:RangesMember
595 Bottom of range Member ifrs-full:BottomOfRangeMember
596 Top of range Member ifrs-full:TopOfRangeMember
597 Statement [Line Items] LineItems us-gaap:StatementLineItems
598 Expected life Concept (xbrli:durationItemType) For Period us-gaap:FairValueAssumptionsExpectedTerm
599 Volatility Concept (Percent) For Period us-gaap:FairValueAssumptionsExpectedVolatilityRate
600 Dividend yield Concept (Percent) For Period us-gaap:FairValueAssumptionsExpectedDividendRate
601 Risk-free interest rate Concept (Percent) For Period us-gaap:FairValueAssumptionsRiskFreeInterestRate
602 000840 - Disclosure - 11. SHAREHOLDERS' EQUITY: Schedule of Assumptions in Fair Value Measurement of Warrants (Details) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure11SHAREHOLDERSEQUITYScheduleOfAssumptionsInFairValueMeasurementOfWarrantsDetails
603 Statement Table

*

*

 us-gaap:StatementTable
604 Classes of share capital Axis ifrs-full:ClassesOfShareCapitalAxis
605 Share capital Member ifrs-full:ClassesOfShareCapitalMember
606 Fair value of each warrant Member fil:FairValueOfEachWarrantMember
607 Range Axis ifrs-full:RangeAxis
608 Ranges Member ifrs-full:RangesMember
609 Bottom of range Member ifrs-full:BottomOfRangeMember
610 Top of range Member ifrs-full:TopOfRangeMember
611 Statement [Line Items] LineItems us-gaap:StatementLineItems
612 Expected life Concept (xbrli:durationItemType) For Period us-gaap:FairValueAssumptionsExpectedTerm
613 Volatility Concept (Percent) For Period us-gaap:FairValueAssumptionsExpectedVolatilityRate
614 Dividend yield Concept (Percent) For Period us-gaap:FairValueAssumptionsExpectedDividendRate
615 Risk-free interest rate Concept (Percent) For Period us-gaap:FairValueAssumptionsRiskFreeInterestRate
616 000850 - Disclosure - 12. PRODUCT REGISTRATION AND DEVELOPMENT: Schedule of Product Registration and Development (Details) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure12PRODUCTREGISTRATIONANDDEVELOPMENTScheduleOfProductRegistrationAndDevelopmentDetails
617 Implied Table Table

*

*

 implied:Table
618 Details Abstract us-gaap:TextBlockAbstract
619 Payroll Concept (Monetary) For Period Debit fil:Payroll
620 Product registration and licensing fees Concept (Monetary) For Period Debit fil:ProductRegistrationAndLicensingFees
621 Product registration and development Concept (Monetary) For Period Debit ifrs-full:ResearchAndDevelopmentExpense
622 000860 - Disclosure - 13. SELLING AND MARKETING EXPENSES: Schedule of Selling and Marketing Expense (Details) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure13SELLINGANDMARKETINGEXPENSESScheduleOfSellingAndMarketingExpenseDetails
623 Implied Table Table

*

*

 implied:Table
624 Details Abstract us-gaap:TextBlockAbstract
625 Payroll (sales personnel) Concept (Monetary) For Period Debit fil:PayrollSalesPersonnel
626 Marketing and advertising Concept (Monetary) For Period Debit fil:MarketingAndAdvertising
627 Distribution Concept (Monetary) For Period Debit fil:Distribution
628 Travel Concept (Monetary) For Period Debit fil:Travel
629 Selling and marketing Concept (Monetary) For Period Debit ifrs-full:SellingExpense
630 000870 - Disclosure - 14. GENERAL AND ADMINISTRATIVE EXPENSES: Schedule of General and Administrative Expenses (Details) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure14GENERALANDADMINISTRATIVEEXPENSESScheduleOfGeneralAndAdministrativeExpensesDetails
631 Implied Table Table

*

*

 implied:Table
632 Details Abstract us-gaap:TextBlockAbstract
633 Management and consulting fees Concept (Monetary) For Period Debit fil:ManagementAndConsultingFees
634 Payroll Concept (Monetary) For Period Debit fil:Payroll1
635 Bad debt Concept (Monetary) For Period Debit fil:BadDebt
636 Investor relations Concept (Monetary) For Period Debit fil:InvestorRelations
637 Office maintenance Concept (Monetary) For Period Debit fil:OfficeMaintenance
638 Legal, audit and accounting Concept (Monetary) For Period Debit fil:LegalAuditAndAccounting
639 Travel Concept (Monetary) For Period Debit fil:Travel1
640 Insurance Concept (Monetary) For Period Debit fil:Insurance
641 Seminars and conferences Concept (Monetary) For Period Debit fil:SeminarsAndConferences
642 Rent Concept (Monetary) For Period Debit fil:Rent
643 Filing and registration fees Concept (Monetary) For Period Debit fil:FilingAndRegistrationFees
644 Amortization Concept (Monetary) For Period Debit fil:Amortization
645 Bank service charges Concept (Monetary) For Period Debit fil:BankServiceCharges
646 Foreign exchange Concept (Monetary) For Period Debit fil:ForeignExchange
647 General and administrative Concept (Monetary) For Period Debit ifrs-full:GeneralAndAdministrativeExpense
648 000880 - Disclosure - 15. RELATED PARTY TRANSACTIONS: Schedule of Related Party Transactions (Details) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure15RELATEDPARTYTRANSACTIONSScheduleOfRelatedPartyTransactionsDetails
649 Implied Table Table

*

*

 implied:Table
650 Details Abstract us-gaap:TextBlockAbstract
651 Management and consulting fees Concept (Monetary) For Period Debit fil:ManagementAndConsultingFees1
652 Rent Concept (Monetary) For Period Debit fil:Rent1
653 Salaries and benefits Concept (Monetary) For Period Debit fil:SalariesAndBenefits
654 Share-based compensation Concept (Monetary) For Period Debit fil:ShareBasedCompensation1
655 Related Party Expenses Concept (Monetary) For Period Debit fil:RelatedPartyExpenses
656 000890 - Disclosure - 15. RELATED PARTY TRANSACTIONS (Details) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure15RELATEDPARTYTRANSACTIONSDetails
657 Implied Table Table

*

*

 implied:Table
658 Details Abstract us-gaap:TextBlockAbstract
659 Due to related parties included in accounts payable and accrued liabilities Concept (Monetary) As Of Credit fil:DueToRelatedPartiesIncludedInAccountsPayableAndAccruedLiabilities
660 000900 - Disclosure - 17. COMMITMENTS: Schedule of future minimum lease payments (Details) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure17COMMITMENTSScheduleOfFutureMinimumLeasePaymentsDetails
661 Statement Table

*

*

 us-gaap:StatementTable
662 Maturity Axis ifrs-full:MaturityAxis
663 Aggregated time bands Member ifrs-full:AggregatedTimeBandsMember
664 Not later than one year Member ifrs-full:NotLaterThanOneYearMember
665 Later than one year and not later than five years Member ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember
666 Statement [Line Items] LineItems us-gaap:StatementLineItems
667 Total future minimum lease payments Concept (Monetary) For Period Debit fil:TotalFutureMinimumLeasePayments
668 000910 - Disclosure - 18. FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT: Schedule of aging of accounts receivable (Details) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure18FINANCIALINSTRUMENTSANDFINANCIALRISKMANAGEMENTScheduleOfAgingOfAccountsReceivableDetails
669 Statement Table

*

*

 us-gaap:StatementTable
670 Classes of financial instruments Axis ifrs-full:ClassesOfFinancialInstrumentsAxis
671 Financial instruments, class Member ifrs-full:ClassesOfFinancialInstrumentsMember
672 Current Member fil:Current1Member
673 0 - 30 days past due Member fil:N030DaysPastDueMember
674 31 - 60 days past due Member fil:N3160DaysPastDueMember
675 61 - 90 days past due Member fil:N6190DaysPastDueMember
676 Over 90 days past due Member fil:Over90DaysPastDueMember
677 Statement [Line Items] LineItems us-gaap:StatementLineItems
678 Trade receivables Concept (Monetary) As Of Debit ifrs-full:TradeReceivables
679 000920 - Disclosure - 18. FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Details) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure18FINANCIALINSTRUMENTSANDFINANCIALRISKMANAGEMENTDetails
680 Implied Table Table

*

*

 implied:Table
681 Details Abstract us-gaap:TextBlockAbstract
682 Allowance for doubtful accounts receivable Concept (Monetary) As Of Credit fil:AllowanceForDoubtfulAccountsReceivable1
683 Accounts payable and accrued liabilities Concept (Monetary) As Of Credit ifrs-full:TradeAndOtherCurrentPayables
684 Asset acquisition liability Concept (Monetary) As Of Credit ifrs-full:OtherLiabilities
685 000930 - Disclosure - 19. SUPPLEMENTAL CASH FLOW INFORMATION: Schedule of Supplemental Cash Flow Information (Details) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure19SUPPLEMENTALCASHFLOWINFORMATIONScheduleOfSupplementalCashFlowInformationDetails
686 Implied Table Table

*

*

 implied:Table
687 Details Abstract us-gaap:TextBlockAbstract
688 Cash paid for interest Concept (Monetary) For Period Debit ifrs-full:InterestExpense
689 Cash paid for income taxes Concept (Monetary) For Period Debit ifrs-full:CurrentTaxExpenseIncome
690 000940 - Disclosure - 19. SUPPLEMENTAL CASH FLOW INFORMATION (Details) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure19SUPPLEMENTALCASHFLOWINFORMATIONDetails
691 Implied Table Table

*

*

 implied:Table
692 Details Abstract us-gaap:TextBlockAbstract
693 Finder's warrants, number issued Concept (Shares) As Of fil:FinderSWarrantsNumberIssued
694 Finder's warrants, fair value Concept (Monetary) As Of Credit fil:FinderSWarrantsFairValue
695 Purchase consideration - Shares to be issued Concept (Monetary) As Of Debit fil:PurchaseConsiderationSharesToBeIssued
696 Purchase consideration - Asset acquisition liability Concept (Monetary) As Of Debit fil:PurchaseConsiderationAssetAcquisitionLiability
697 Write-downs (reversals of write-downs) of inventories Concept (Monetary) For Period Debit ifrs-full:WritedownsReversalsOfInventories
698 Impairment of intellectual property Concept (Monetary) For Period ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
699 000950 - Disclosure - 20. INCOME TAXES: Schedule of Income Tax Reconciliation (Details) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure20INCOMETAXESScheduleOfIncomeTaxReconciliationDetails
700 Implied Table Table

*

*

 implied:Table
701 Details Abstract us-gaap:TextBlockAbstract
702 Net loss and comprehensive loss for the period Concept (Monetary) For Period Credit ifrs-full:ProfitLoss
703 Statutory tax rate Concept (Percent) For Period fil:StatutoryTaxRate
704 Expected income tax (recovery) Concept (Monetary) For Period Credit fil:ExpectedIncomeTaxRecovery
705 Non-deductible items Concept (Monetary) For Period Credit fil:NonDeductibleItems
706 Change in estimates Concept (Monetary) For Period Credit fil:ChangeInEstimates
707 Share issue costs Concept (Monetary) For Period Credit fil:ShareIssueCosts
708 Loss expired Concept (Monetary) For Period Credit fil:LossExpired
709 Change in statutory rates and other Concept (Monetary) For Period Credit fil:ChangeInStatutoryRatesAndOther
710 Change in deferred tax asset not recognized Concept (Monetary) For Period Credit fil:ChangeInDeferredTaxAssetNotRecognized
711 000960 - Disclosure - 20. INCOME TAXES: Schedule of Deferred Tax Assets and Liabilities (Details) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure20INCOMETAXESScheduleOfDeferredTaxAssetsAndLiabilitiesDetails
712 Implied Table Table

*

*

 implied:Table
713 Details Abstract us-gaap:TextBlockAbstract
714 Non-capital loss carry-forwards Concept (Monetary) As Of Debit fil:NonCapitalLossCarryForwards
715 Property and equipment Concept (Monetary) As Of Debit fil:PropertyAndEquipment
716 Intangible asset Concept (Monetary) As Of Debit fil:IntangibleAsset
717 Financing costs Concept (Monetary) As Of Debit fil:FinancingCosts
718 Deferred tax assets Concept (Monetary) As Of Debit ifrs-full:DeferredTaxAssets
719 Deferred tax asset not recognized Concept (Monetary) As Of Credit fil:DeferredTaxAssetNotRecognized
720 Net deferred tax asset (liability) Concept (Monetary) As Of Debit ifrs-full:NetDeferredTaxAssets
721 000970 - Disclosure - 21. SUBSEQUENT EVENTS (Details) Network

*

*

 http://www.vancpharmaceuticals.com/20171231/role/idr_Disclosure21SUBSEQUENTEVENTSDetails
722 Statement Table

*

*

 us-gaap:StatementTable
723 Non-adjusting events after reporting period Axis ifrs-full:NonadjustingEventsAfterReportingPeriodAxis
724 Non-adjusting events after reporting period Member ifrs-full:NonadjustingEventsMember
725 In January and April 2018 Member fil:InJanuaryAndApril2018Member
726 In February 2018 Member fil:InFebruary2018Member
727 In April 2018 Member fil:InApril2018Member
728 On April 15, 2018 Member fil:OnApril152018Member
729 On April 27, 2018 Member fil:OnApril272018Member
730 April 2018 Member fil:April2018Member
731 Statement [Line Items] LineItems us-gaap:StatementLineItems
732 Description of significant events and transactions Concept (Text/String) For Period ifrs-full:DescriptionOfSignificantEventsAndTransactions
733 Increase (decrease) in number of ordinary shares issued Concept (Shares) For Period ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
734 Stock options granted Concept (Shares) For Period fil:StockOptionsGranted
735 Share purchase warrants issued Concept (Shares) For Period fil:SharePurchaseWarrantsIssued

*

*